apixaban is an anticoagulant for the treatment of venous thromboembolic events. it is taken by mouth. it is a direct factor xa inhibitor. apixaban was approved in the u.s. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (dvt) and p
